Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Invested Capital (2016 - 2025)

Historic Invested Capital for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $89.2 million.

  • Akebia Therapeutics' Invested Capital rose 84070.72% to $89.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.2 million, marking a year-over-year increase of 84070.72%. This contributed to the annual value of -$10.5 million for FY2024, which is 35596.49% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Invested Capital of $89.2 million as of Q3 2025, which was up 84070.72% from $76.3 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Invested Capital ranged from a high of $213.9 million in Q1 2021 and a low of -$1.5 billion during Q3 2022
  • Its 5-year average for Invested Capital is -$12.8 million, with a median of $71.1 million in 2025.
  • Per our database at Business Quant, Akebia Therapeutics' Invested Capital plummeted by 118276.19% in 2022 and then surged by 236248.7% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Invested Capital stood at $171.6 million in 2021, then plummeted by 58.43% to $71.3 million in 2022, then crashed by 94.25% to $4.1 million in 2023, then tumbled by 355.96% to -$10.5 million in 2024, then skyrocketed by 950.49% to $89.2 million in 2025.
  • Its Invested Capital was $89.2 million in Q3 2025, compared to $76.3 million in Q2 2025 and $71.1 million in Q1 2025.